Antitumoral immune response (None established; sometimes abbreviated as "anti-tumor immune response" in literature, but no standard abbreviation.)

The **antitumoral immune response**, also known as anti-tumor immunity or tumor immunity, refers to the collective actions by which an organism's **immune system recognizes and eliminates malignant cells**, thereby suppressing cancer development and progression. This involves both innate and adaptive arms of immunity—including cytotoxic T lymphocytes (CD8+), helper T cells (CD4+), natural killer cells, dendritic cells presenting tumor-associated antigens via MHC molecules—and is regulated through complex interactions within the **tumor microenvironment**, which includes both cellular elements like macrophages/Tregs/myeloid-derived suppressors and non-cellular factors such as cytokines/chemokines[1][5][6]. Tumors can evade or suppress these responses through various mechanisms including upregulation of inhibitory ligands like PD-L1/CTLA4 that dampen T cell function ("checkpoint inhibition"), recruitment of regulatory/suppressive myeloid populations that inhibit effector functions, secretion of immunosuppressive cytokines such as IL-10/TGF-beta, metabolic reprogramming within the microenvironment limiting effective infiltration/proliferation/functionality of cytotoxic lymphocytes ("cold tumors"), among others[3][5]. Modern cancer immunotherapies seek either to unleash suppressed endogenous responses—by blocking checkpoints—or actively stimulate new ones using vaccines/cytokines/adoptive transfer approaches. The effectiveness varies widely depending on individual patient/tumor characteristics including mutational burden ("neoantigen load"), degree/type/location/infiltration status ("hot vs cold tumors"), expression levels/signatures associated with interferon signaling or exhaustion markers among infiltrating lymphocytes.[2][4] In summary: while central for oncology research/drug development strategy designations (“immuno-oncology”), “antitumoral immune response” itself does *not* represent an actionable single-molecule therapeutic target but rather describes an overarching physiological phenomenon encompassing many potential targets at different points along its pathway.[2]

Other names

Anti-tumor immune responseAnticancer immune responseTumor immunity

Not applicable directly—mechanisms include: - Blocking inhibitory signals on T cells to restore/enhance cytotoxic activity against tumor cells (immune checkpoint blockade) - Stimulating effector T cell proliferation/function - Modifying the tumor microenvironment to favor antitumor activity Again, these are mechanisms acting on parts of the overall process.